Ongoing Funded Projects
Progesterone for the Prevention of Miscarriage and Preterm Birth in Women with First Trimester Bleeding
(PREEMPT Trial)
Principal investigator: ABENHAIM, Haim.
Co- Investigators: AUDIBERT, Francois FRASER WILLIAM, Donald GAGNON, Robert KLAM, Stephanie LEROUX, Nathalie PLAT, Robert William
Institution: Jewish General Hospital (Montreal)
Agency: Canadian Institutes of Health Research (CIHR)
Amount: 2014-15, $240,661
Synopsis: Miscarriages and preterm births are common and serious events affecting women, families, and healthcare systems on many levels. One of the risk factors for miscarriage and preterm birth is bleeding in the first trimester of pregnancy. Progesterone, a hormone that plays a key role during pregnancy, has been proposed as a possible medication to be used in pregnancy to prevent miscarriage and preterm birth among women who have bleeding in their first trimester of pregnancy. Unfortunately, unless sound clinical evidence is obtained through a clinical trial, whether or not progesterone can indeed prevent miscarriage and preterm birth remains uncertain and thus is not a recommended treatment in women with early pregnancy bleeding. The purpose of our study is to evaluate the effect of progesterone for the prevention of miscarriage and preterm birth among women with early pregnancy bleeding. We will carry out a clinical trial in which 850 women will be randomized to receive either progesterone supplementation (425 women) or a similarly appearing placebo (425 women) and the outcome of their pregnancy will be compared. We hypothesize that progesterone will be beneficial in reducing miscarriage rates and preterm birth rates. Our findings will have important applications to women and their families worldwide who suffer through the hardships of miscarriage and preterm births.
Are Cesarean Deliveries Associated with a Long-Term increased risk of small bowel obstruction?
Principal investigator: ABENHAIM, Haim.
Co-investigators: PLATT, Robert; SUISSA, Samy; TULANDI, Togas; WILCHESKY, Machelle
Institution: Jewish General Hospital (Montreal)
Agency: The Canadian Institutes of Health Research (CIHR)
Amount: 2012-14, $156,813
Synopsis: Cesarean deliveries are becoming one of the most commonly performed surgeries in Westernized countries today with an estimated 1 in 4 births today being performed by cesarean delivery. While most research suggests that cesarean deliveries are considered both safe for the mother and baby, the long term consequences of cesarean deliveries has not well been established. We have long known that most abdominal surgeries results in internal scar formation which can lead to the development of small bowel obstruction, a clinical condition requiring recurrent hospital admissions and sometimes multiple operations. Whether cesarean deliveries can increase the risk of developing small bowel obstruction remains unknown. The purpose of our study is to evaluate the association between cesarean deliveries and the development of small bowel obstruction. The importance of this study is to gain enough information to properly inform women who chose to undergo a cesarean delivery not only of the short term risks but also of the long term risks associated with this common surgery. Women and physicians alike should be well informed of the long term risks of cesarean delivery so that an informed decision can be made that will take into consideration not only the potential benefits of the procedure but as well the potential long term risks that may result from the cesarean delivery.
Hormone Replacement Therapy and Breast Cancer: Bioidentical vs Synthetic Hormones
Principal investigator: ABENHAIM, Haim.
Co-investigators: Azoulay, Laurent Suissa, Samy Tulandi, Togas
Agency: Canadian Cancer Society
Institution: Jewish General Hospital (Montreal)
Amount: 2014-16, $211,738
Synopsis: Hormone replacement therapy is commonly prescribed for the treatment of hot flushes and menopausal symptoms. Dr Abenhaim proposes to examine the effect of different hormone replacement therapies on the risk of breast cancer and to compare the incidence of breast cancer between users of bioidentical (natural) hormone replacement therapy and users of non-bioidentical (synthetic) hormone replacement therapy. In recent years, there has been much concern over the safety of these medications, particularly in the reported increased risk of breast cancer. Unfortunately, most of these studies were done on synthetic or animal derived hormones and have been shown to incur upon women an increased risk of breast cancer. While there are some studies that suggest that bioidentical hormones may be safer, there are no good studies that have appropriately evaluated this question. The purpose of Dr Abenhaim's study is to determine the effect of the hormone type (natural versus synthetic) on the risk of breast cancer. He and his team will conduct a study on approximately 1 million women of which an estimated 12,000 women will have had breast cancer and examine the effect of different hormones on the risk of breast cancer. The results of this research will be important as they may provide important information on the safety of these medications which remain the most effective treatments for hot flushes and menopausal symptoms. Should bioidentical formulations be found to be safer, switching formulations and initiating the safer formulations in new users would lead to an overall reduction in the risks of breast cancer related to HRT. However, more importantly, it will provide an effective treatment for vasomotor symptoms in women going through menopause.
Mentoring program to develop expertise in design and planning of a
randomized controlled trial on vaginal births after cesarean section
Principal investigator: ABENHAIM Haim
Co-investigator: FRASER, William Donald
Institution: Université de Montréal
Agency: CIHR
Amount: 2008-10, $140,000
Mentoring program to develop expertise in design and planning of a
randomized controlled trial on vaginal births after cesarean section
Principal investigators: ABENHAIM, Haim FRASER, William Donald
Institution: Université de Montréal
Agency: CIHR
Amount: 2007-10, $20,000
Collaborations
The use of highly prolactin-elevating antipsychotics and the risk of ovarian and endometrial cancer
Principal investigator: AZOULAY, Laurent
Co-Investigators: ABENHAIM, Haim Arie
GALBAUT DU FORT, Guillaume
SUISSA Samy
Institution: Jewish General Hospital (Montreal)
Agency: CIHR
Amount: 2013-14, $117,400
Processus d'aide à la décision, gestion du RISque obstétrical et du Mode d'Accouchement
après césarienne au Québec (PRISMA)
Principal investigators: BUJOLD, Emmanuel
CHAILLET
, Nils
Co-Investigators:
ABENHAIM, Haim Arie
AUDIBERT, Francois
BEAUDOIN, Francois
BÉDARD, Marie-Josée
CHAMPAGNE, François
DUGAS, Marylène
DUPERRON, Louise
FRASER, William Donald
GAGNON, Robert
GAGNÉ, Guy-Paul
GAUTHIER, Robert Jacques
GIRARD, Isabelle
GROBMAN, William A
JOHRI, Mira
MASSE, Benoît Robert
MONNIER, Patricia Odile
PASQUIER, Jean Charles
ROZENBERG, Patrick
SHORTEN, Allison
Institution: Université de Sherbrooke
)Agency: CIHR
Amount: 2013-14, $117,400
CIHR - Quebec Training Network in Perinatal Research
Principal investigators:
BUJOLD, Emmanuel
CHAILLET, Nils
FRASER, William Donald
GAGNON, Robert
HATEM, Marie
MONNIER, Patricia Odile
MUCKLE, Gina
MURPHY, Bruce Daniel
TREMBLAY, Yves
WILLIAMS-JONES, Bryn
Co-Investigators:
ABENHAIM, Haim Arie
AVARD, Denise M.
BILODEAU, Jean-François
BÉRARD, Anick
CÔTÉ, Sylvana
DUBOIS, Lise
FISHER, William Arthur
JULIEN, Pierre
KIBAR, Zoha
LUO, Zhong-Cheng
MARC, Isabelle
MOUTQUIN, Jean-Marie
NUYT, Anne Monique
PIEDBOEUF, Bruno
PIERSON, Roger Allen
SEGUIN, Jean Richard
TREMBLAY, Jacques J.
TREMBLAY, Richard E.
TROTTIER, Helen
TSANG, Benjamin Kwok
Institution: Hôpital Sainte-Justine (Montréal)
Agency: CIHR
Amount: 2001-14, $3,189,883
Depression Screening and Patient Outcomes in Pregnancy and Postpartum: A Systematic Review
Principal investigators:
CIOFANI, Luisa
THOMBS, Brett David
Co-Investigators:
ABENHAIM, Haim Arie
COYNE, James
FEELEY, Nancy L
FRUNCHAK, Valerie
GILBODY, Simon Martin
HEWITT, Catherine
MACMILLAN, Harriet L.
SCHINAZI, Joy
STEWART, Donna Eileen
ZELKOWITZ, Phyllis
Institution: Jewish General Hospital (Montreal)
Agency: CIHR
Amount: 2009-10,
$97,766
The integrated Research Network on Perinatology
Principal investigators:
DUBOIS, Lise
FRASER, William Donald
GANLEY SOMERVILLE, Margaret Anne
LUO, Zhong-Cheng
MICHAUD, Jacques L.
MOUTQUIN, Jean-Marie
MUCKLE, Gina
SEGUIN, Jean Richard
TRASLER, Jacquetta M.
TREMBLAY, Richard E.
Co-Investigators:
ABENHAIM, Haim Arie
ABRAHAMOWICZ, Michal M. A.
ANDELFINGER, Gregor Ulrich
ARBUCKLE, Tye Elaine
AUDIBERT, Francois
AVARD, Denise M.